Introduction: SARS-CoV-2 infection seems to have a brain tropism involving several pathophysiological mechanisms. The objective of our work was to study the epidemiological, clinical, paraclinical and evolutionary aspects of stroke patients following SARS-CoV-2 infection. Methodology: This was a retrospective descriptive and analytical study from 26 March 2020 to 30 September 2021, which took place at the Ziguinchor epidemic treatment center. All patients infected with SARS-CoV-2 confirmed by RT-PCR with clinical signs suggestive of stroke and confirmed by brain CT scan were included in our study. Patients with incomplete or unexploitable records were excluded. Results: Twenty-four patients were collected out of a total of 186 severe cases, a prevalence of 12.90%. All patients had an ischemic stroke. The mean age was 69 ± 6 years with extremes of 58 and 84 years. The sex ratio (M/F) was 1.2. Diabetes and hypertension were co-morbidities in 87.50% and 25% of cases respectively. Clinical signs were dominated by a hemi-corporal deficit (87.5%) and dyspnea (75%). All patients were on anticoagulation and corticosteroids. The evolution was favourable in 62.5% of patients against 37.5% of death. Conclusion: SARS-CoV-2 infection is responsible for numerous neurovascular complications and this risk increases with the presence of diabetes, arterial hypertension and emboligenic heart disease. Corticosteroid therapy and anticoagulation have allowed us to improve the prognosis of patients.
References
[1]
Sellal, F., Tazii, R., Ahle, G., et al. (2020) Neurological Manifestations in the COVID-19 Pandemic. Neurological Practice, 11, 147-151. https://doi.org/10.1016/j.praneu.2020.08.011
[2]
Fogoum, Y.F., Njoya, A.V. and Noubom, M. (2021) Neurological Manifestations of COVID-19 in the Regional Hospital of Bafoussam, Cameroon. Revue Neurologique, 177, S72. https://doi.org/10.1016/j.neurol.2021.02.242
[3]
Zieda, S., Messelmani, M. and Akkari, M. (2021) Inaugural Stroke of COVID-19 Infection: A Study of 9 Cases. Revue Neurologique, 177, S92-S93. https://doi.org/10.1016/j.neurol.2021.02.294
[4]
Li, Y., Wang, M., Zhou, Y., et al. (2020) Acute Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational Study. Stroke and Vascular Neurology, 5, 279-284. https://doi.org/10.2139/ssrn.3550025
[5]
Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., et al. (2020) Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurologie, 77, 683-690. https://doi.org/10.1001/jamaneurol.2020.1127
[6]
Romero-Sánchez, C.M., Díaz-Maroto, I., Fernández-Díaz, E., Sánchez-Larsen, A., Layos-Romero, A., García-García, J., et al. (2020) Neurologic Manifestations in Hospitalized Patients with COVID-19: The Albacovid Registry. Neurology, 95, e1060-e1070. https://doi.org/10.1212/WNL.0000000000009937
[7]
Qureshi, A.I., Abd-Allah, F., Al-Senani, F., Aytac, E., Borhani-Haghighi, A., Ciccone, A., et al. (2020) Management of Acute Ischemic Stroke in Patients with COVID-19 Infection: Report of an International Panel. International Journal of Stroke, 15, 540-554. https://doi.org/10.1177/1747493020923234
[8]
Chou, S.H.-Y., Beghi, E., Helbok, R. and Moro, E. (2021) Global Incidence of Neurological Manifestations among Patients Hospitalized with COVID-19. A Report for the GCS-Neuro COVID Consortium and the ENERGY Consortium. JAMA Network Open, 4, e2112-e2131.
[9]
Xiao, M., Zhang, S., Xia, P., Cao, W., Jiang, W., et al. (2020) Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. The New England Journal of Medicine, 382, e38. https://doi.org/10.1056/NEJMc2007575
[10]
Yaghi, S., Ishida, K., Torres, J., Grory, B.M., Raz, E., Humbert, K., et al. (2020) SARS2-CoV-2 and Stroke in a New York Healthcare System. Stroke, 51, 2002-2011. https://doi.org/10.1161/STROKEAHA.120.030335
[11]
Qureshi, A.I., Baskett, W.I., Huang, W., Shyu, D., Myers, D., Raju, M., et al. (2021) Acute Ischemic Stroke and COVID-19: An Analysis of 27676 Patients. Stroke, 52, 905-912. https://doi.org/10.1161/STROKEAHA.120.031786
[12]
Qin, C., Zhou, L., Hu, Z., Yang, S., Zhang, S., Chen, M., et al. (2020) Clinical Characteristics and Outcomes of COVID-19 Patients with a History of Stroke in Wuhan, China. Stroke, 51, 2219-2223. https://doi.org/10.1161/STROKEAHA.120.030365
[13]
Beyrouti, R., Adams, M.E., Benjamin, L., Cohen, H., Farmer, S.F., Goh, Y.Y., et al. (2020) Characteristics of Ischaemic Stroke Associated with COVID-19. Journal of Neurology, Neurosurgery & Psychiatry, 91, 889-891. https://doi.org/10.1136/jnnp-2020-323586
[14]
Carod-Artal, F.J. (2020) Neurological Complications of Coronavirus and COVID-19. Revue Neurologique, 70, 311-322. https://doi.org/10.33588/rn.7009.2020179
[15]
Lee, S.G., Fralick, M. and Sholzberg, M. (2020) Coagulopathy Associated with COVID-19. CMAJ, 192, E583-E583. https://doi.org/10.1503/cmaj.200685
[16]
Couvreur, P. and Louvard, D. (344) COVID-19 and Drugs (2021): Pathophysiology and Therapeutic Approaches. Comptes Rendus Biologies, 344, 27-42. https://doi.org/10.5802/crbiol.38
[17]
Fara, M.G., Stein, L.K. and Skliut, M. (2020) Macrothrombosis and Stroke in Patients with Mild Covid-19 Infection. Journal of Thrombosis and Haemostasis, 18, 2031-2033. https://doi.org/10.1111/jth.14938
[18]
Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., et al. (2021) High Risk of Thrombosis in Patients with Severe SARS-CoV-2 Infection: A Multicenter Prospective Cohort Study. Intensive Care Medicine, 46, 1089-1098. https://doi.org/10.1007/s00134-020-06062-x
[19]
Magro, C., Mulvey, J.J., Berlin, D., Nuovo, G., Salvatore, S., Harp, J., et al. (2020) Complement Associated Microvascular Injury and Thrombosis in the Pathogenesis of Severe COVID-19 Infection: A Report of Five Cases. Translational Research, 220, 1-13. https://doi.org/10.1016/j.trsl.2020.04.007
[20]
WHO (2020) Rapid Evidence Appraisal for COVID-19 Therapies (REACT). Working Group Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-Analysis, JAMA, 324, 1330-1341.
